Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.50 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.50 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.50 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.50 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.50 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.50 |
| ▸ | PTPN1 | P18031 | 6/20 | 0.47 |
| ▸ | GSK3B | P49841 | 9/20 | 0.46 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.43 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.43 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9731669 | 0.82 | ADORA3 (0.50) | ADORA3ADORA2AADORA2BADORA1GRIA3 | |
| SCHEMBL12201007 | 0.82 | ADORA3 (0.50) | ADORA3ADORA2AADORA2BADORA1GRIA3 | |
| SCHEMBL483190 | 0.79 | PTPN1 (0.56) | PTPN1GSK3B | |
| SCHEMBL548490 | 0.77 | GRIA3 (0.56) | ADORA3ADORA2AADORA2BADORA1GRIA3 | |
| SCHEMBL2733233 | 0.76 | GRIA3 (0.54) | ADORA3ADORA2AADORA2BADORA1GRIA3 | |
| SCHEMBL30356124 | 0.76 | GRIA3 (0.54) | ADORA3ADORA2AADORA2BADORA1GRIA3 | |
| SCHEMBL548652 | 0.76 | GRIA3 (0.54) | ADORA3ADORA2AADORA2BADORA1GRIA3 | |
| Hydrochloric Acid SCHEMBL562597 | 0.76 | GRIA3 (0.54) | ADORA3ADORA2AADORA2BADORA1GRIA3 | |
| SCHEMBL1708565 | 0.76 | GRIA3 (0.54) | ADORA3ADORA2AADORA2BADORA1GRIA3 | |
| SCHEMBL2834465 | 0.75 | ADORA3 (0.61) | ADORA3ADORA2AADORA2BADORA1GRIA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9056859-B2 | Inhibitors of the renal outer medullary potassium channel | MERCK SHARP & DOHME CORP. (US) | 2015-06-16 | — | — | US | disclosed |
| EP-2632464-B1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME (US) | 2015-04-29 | — | — | EP | disclosed |
| EP-2632464-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | Merck Sharp & Dohme Corp. (US) | 2013-09-04 | — | — | EP | disclosed |
| US-20130217680-A1 | Inhibitors of the Renal Outer Medullary Potassium Channel | MERCK SHARP & DOHME LLC | 2013-08-22 | — | — | US | disclosed |
| WO-2012058134-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME CORP. (US) | 2012-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130217680-A1 | Inhibitors of the Renal Outer Medullary Potassium Channel | KCNJ11, KCNJ1, KCNJ2 | ADORA3 1729/4885ADORA2A 2066/4885ADORA2B 1582/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.